We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avraham Pharmaceuticals Raises $4.5 Million
News

Avraham Pharmaceuticals Raises $4.5 Million

Avraham Pharmaceuticals Raises $4.5 Million
News

Avraham Pharmaceuticals Raises $4.5 Million

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Avraham Pharmaceuticals Raises $4.5 Million"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avraham Pharmaceuticals Ltd. has announced that Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum's biotech holdings company and the Technion Research and Development Foundation Ltd. (TRDF) and others invested an additional $4.5 million in the Company. Following the current investment round, Yissum and Integra Holdings will now hold 46% of the shares of Avraham Pharmaceuticals.

Avraham Pharmaceuticals will use the newly invested capital to advance a Phase 2b study of ladostigil, a novel molecule designed for the treatment of mild cognitive impairment (MCI) and early stages of Alzheimer's disease. In July 2014, the Company announced successful interim results in this Phase 2b clinical trial for the evaluation of the safety and efficacy of ladostigil in MCI patients.

The on-going Phase 2b trial is a 3 years, multi-center, randomized, double-blind, placebo-controlled trial and includes 210 patients in 16 centers in Germany, Austria and Israel. An independent expert committee concluded that there are no safety issues preventing continuation of the trial after evaluated safety data on all patients participating in the trial and that have completed at least 1 year of treatment.

Interim results also point to a positive trend as to the efficacy of the drug, as evident by various clinical parameters and relevant biomarkers. This includes reduced loss of brain volume as determined by MRI, improved immune system parameters and trends in improvement of cognitive parameters.

Yaacov Michlin, Chairman of Avraham Pharmaceuticals and Chief Executive Officer of Yissum, commented: "This investment marks a further vote of confidence from our existing investors in Avraham and ladostigil and will enable us to continue to advance our on-going Phase 2 study with patients suffering from MCI, that is advancing on schedule. There is currently no treatment available for MCI, and we have high hopes that ladostigil will become the first drug to alleviate MCI symptoms and prevent progression to Alzheimer's disease, to the benefit of millions of people suffering from this condition.”

Dr. Yona Geffen, Avraham Pharmaceuticals Chief Executive Officer, said: "We have begun discussion with potential licensing partners, based on the encouraging interim analysis results showing positive trends in the benefit of the drug treatment compared to placebo already after 12 months of treatment. We look forward to the next interim analysis of the study, expected in the third quarter of 2015 following 2 years of treatment, and the final results expected in the third quarter of 2016.”

Earlier this month, Avraham Pharmaceuticals held an international investigators meeting in Berlin, for the purpose of briefing the trials’ investigators on the Phase 2b interim analysis results. Around 50 physicians and other clinical staff from a total of 16 sites in Europe and Israel participated in the meeting.

Advertisement